mProX™ Human RPS6KA4 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX389	Magic™ Human MSK2(RPS6KA4) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HCT116

Target Classification

Kinase Cell Lines

Target Research Area

Pain and Addiction Research

Related Diseases

Coffin-Lowry Syndrome

Gene ID

Human:8986

UniProt ID

Human:O75676

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The RPS6KA4 gene has various applications in different medical fields. In acute myeloid leukemia (AML), a signature constructed based on the RPS6KA4 gene family can be used to predict the prognosis of AML patients and their response to treatment. Additionally, RPS6KA4 may serve as a novel drug target for AML. In hepatocellular carcinoma (HCC), genetic variants in RPS6KA4 are associated with survival rates of HBV-related HCC patients. Higher expression of RPS6KA4 is associated with poor prognosis in HCC patients. Furthermore, RPS6KA4 is implicated in the pathogenesis of HCC and may be involved in epigenetics, cell adhesion, tumor-driven GTPase pathways, and infection-related carcinogenesis. Lastly, RPS6KA4 is also associated with Beh√βet's disease uveitis, where a specific SNP in the NONHSAT159216.1 lncRNA gene, regulated by RPS6KA4, confers susceptibility to the disease.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human RPS6KA4 Stable Cell Line (S01YF-1023-PY14). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Smith (Verified Customer)

Is RPS6KA4 overexpression related to any specific cancer types? Jan 18 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Overexpression of RPS6KA4 is significantly associated with poor prognosis in hepatocellular carcinoma (HCC), including higher T stage, pathological stage, AFP value, and vascular invasion. Jan 18 2022

chat Skyler Jones (Verified Customer)

How does RPS6KA4 overexpression affect survival rates in cancer patients? Apr 08 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Patients with hepatocellular carcinoma showing RPS6KA4 overexpression have worse overall survival, disease-specific survival, and progress-free interval. Apr 08 2023

Published Data

Fig.1 a-LA inhibition of RPS6KA4 and its association with p53 induction.

Inhibition of RPS6KA4 by a-LA and its correlation with p53 activation was examined in HCT116 cells, both p53-WT and p53-deficient variants, via transfection with escalating doses of WT-RPS6KA4 expression vectors. Subsequent to a 24-hour transfection period, cells were subjected to treatment with a-LA (100 mmol/l) and 5-FU (100 mmol/l). The levels of RPS6KA4 and p53 expression were assessed through RT-PCR and western blot assays conducted 48 hours post-treatment.

Ref: Yoo, Tae-Hyoung, et al. "α-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-κB induction of RPS6KA4." Anti-Cancer Drugs 24.6 (2013): 555-565.

Pubmed: 23599020

DOI: 10.1097/CAD.0b013e32836181eb

Research Highlights

Wu, Shasha. et al. "Comprehensive analysis of the RSK gene family in acute myeloid leukemia determines a prognostic signature for the prediction of clinical prognosis and treatment responses." Hematology (Amsterdam, Netherlands), 2023.
The prognosis of acute myeloid leukemia (AML) continues to be unfavorable, despite significant advancements in basic and translational research on the genetics and pathopoiesis of AML. Numerous targeted therapies have been developed as a result. Therefore, there is a critical need to further investigate the molecular pathogenesis of AML in order to advance the development of innovative treatment strategies. The knowledge gained from this research may lead to improved outcomes for patients.
Wu, Shasha. et al. "Comprehensive analysis of the RSK gene family in acute myeloid leukemia determines a prognostic signature for the prediction of clinical prognosis and treatment responses." Hematology (Amsterdam, Netherlands), 2023.
Pubmed: 37462338 DOI: 10.1080/16078454.2023.2235833

Qiu, Moqin. et al. "Potentially functional genetic variants in RPS6KA4 and MAP2K5 in the MAPK signaling pathway predict HBV-related hepatocellular carcinoma survival." Molecular carcinogenesis, 2023.
Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related deaths, marked by a discouraging 5-year survival rate. Aberrant activation of the mitogen-activated protein kinase (MAPK) signaling pathway fuels the growth and metastatic potential of HCC cells. Consequently, the study undertook a two-stage survival analysis of 10,912 single nucleotide polymorphisms (SNPs) across 79 MAPK pathway genes, assessing their impact on the overall survival (OS) of 866 HBV-related HCC patients, with subsequent functional annotation. Within combined datasets, they uncovered two novel SNPs (RPS6KA4 rs600377 T>G and MAP2K5 rs17300363 A>C) as prognostic factors for HBV-related HCC, conveying adjusted allelic hazard ratios of 1.24 (95% confidence interval [CI] = 1.05-1.46, p = 0.010) and 1.48 (1.15-1.91, p = 0.001), respectively. Moreover, these risk genotypes collectively indicated poor survival in a dose-response pattern (Ptrend < 0.001) within the combined dataset. Supplementary functional analysis revealed that RPS6KA4 rs600377 G and MAP2K5 rs17300363 C alleles correlated with heightened mRNA expression levels in corresponding genes in normal tissues, offering fresh insights into the role of genetic variations within MAPK signaling pathway genes in HBV-related HCC survival.
Qiu, Moqin. et al. "Potentially functional genetic variants in RPS6KA4 and MAP2K5 in the MAPK signaling pathway predict HBV-related hepatocellular carcinoma survival." Molecular carcinogenesis, 2023.
Pubmed: 37278562 DOI: 10.1002/mc.23583